Septerna Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform(TM). Septerna Inc. is based in SOUTH SAN FRANCISCO, Calif.
| Revenue (Most Recent Fiscal Year) | $1.08M |
| Net Income (Most Recent Fiscal Year) | $-71.80M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 775.32 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.49 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -12093.80% |
| Net Margin (Trailing 12 Months) | -12053.03% |
| Return on Equity (Trailing 12 Months) | -31.52% |
| Return on Assets (Trailing 12 Months) | -23.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 22.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 22.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.47 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.56 |
| Earnings per Share (Most Recent Fiscal Year) | $-7.26 |
| Diluted Earnings per Share (Trailing 12 Months) | $-10.09 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 44.58M |
| Free Float | 42.67M |
| Market Capitalization | $562.89M |
| Average Volume (Last 20 Days) | 0.23M |
| Beta (Past 60 Months) | -- |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.30% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |